MedTrace Logo

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

NCT02672839 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-05-18

No results posted yet for this study

Summary

The purpose of this study is to compare relative oral bioavailability of a capsule formulation of LGD-6972 to a solution formulation of LGD-6972.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

DRUG

LGD-6972 Solution

15 mg of LGD-6972

DRUG

LGD-6972 Capsules

15 mg LGD-6972

Sponsors & Collaborators

  • Medpace, Inc.

    collaborator INDUSTRY

  • Ligand Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Lukasz Biernat, M.D. · Medpace Clinical Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02672839 on ClinicalTrials.gov